OnDemand

The January 1, 2023 effective date for the CMS Final Rule on manufacturer coupons and Best Price is rapidly approaching, but the pharmaceutical industry remains largely unclear on how to solve the challenge it creates. Operational limitations, vague measurement, enforcement methods, and an ongoing legal battle have all caused manufacturers to struggle to find ways to balance compliance with maintaining cost-sharing support in a manner that is not overly burdensome for patients to participate in.

Listen OnDemand to TrialCard’s Jason Zemcik, Vice President and Patient Affordability Practice Lead, and IntegriChain’s Jeff Baab, Vice President, Advisory Services outline how industry leaders can build a framework for their organizations to:

• Walkthrough real-world examples of the potential impact of co-pay programs on Best Price
• Assess which solution capabilities are feasible based on three key areas: legal, finance, and patient experience
• Build holistic solution sets that address a variety of patient scenarios and enable flexibility to respond to the uncertain future of this issue

Jeff Baab
Vice President, Advisory Services

Jason Zemcik
Vice President and Patient Affordability Practice Lead

Learn more by reading a market update that details recent CMS Final Rule provisions.